Mapi Hits Milestone For Viatris-Partnered Long-Acting Glatiramer
More Than 600 Patients Now Dosed In Pivotal Phase III Trial
Fresh from a $20m investment from partner Viatris, Mapi Pharma has announced significant progress in its Phase III trial for a long-acting version of Copaxone, which is to be filed through the FDA’s 505(b)(2) hybrid pathway.
